Trial: 201906081

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)



Principal Investigator

Park, Haeseong

Disease Site

Brain and Nervous System; Breast; Colon; Ill-Defined Sites; Kidney; Lip, Oral Cavity and Pharynx; Lung; Other Digestive Organ; Rectum; Soft Tissue; Stomach; Thyroid; Urinary Bladder

Learn more about this study at: